Genetic Variants in theLEPR,CRY1,RNASEL,IL4, andARVCFGenes Are Prognostic Markers of Prostate Cancer-Specific Mortality
Authors:
- Liesel M. FitzGeraldLFLiesel M. FitzGerald
- Rong FuRFRong Fu
- Erika M. KwonEKErika M. Kwon
- Siqun Lilly ZhengSZSiqun Lilly Zheng
- Suzanne KolbSKSuzanne Kolb
- Fredrik WiklundFWFredrik Wiklund
- Pär StattinPSPär Stattin
- William B. IsaacsWIWilliam B. Isaacs
- Jianfeng XuJXJianfeng Xu
- Elaine A. OstranderElaine A. Ostrander
- Ziding FengZFZiding Feng
- 1 September 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 20 (9) , 1928-1936
Abstract
Background: Prostate cancer is the second leading cause of cancer-related deaths in men, accounting for more than 30,000 deaths annually. The purpose of this study was to test whether variation in selected candidate genes in biological pathways of interest for prostate cancer progression could help distinguish patients at higher risk for fatal prostate cancer. Methods: In this hypothesis-driven study, we genotyped 937 single nucleotide polymorphisms (SNPs) in 156 candidate genes in a population-based cohort of 1,309 prostate cancer patients. We identified 22 top-ranking SNPs (P ≤ 0.01, FDR ≤ 0.70) associated with prostate cancer-specific mortality (PCSM). A subsequent validation study was completed in an independent population-based cohort of 2,875 prostate cancer patients. Results: Five SNPs were validated (P ≤ 0.05) as being significantly associated with PCSM, one each in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes. Compared with patients with 0 to 2 of the at-risk genotypes those with 4 to 5 at-risk genotypes had a 50% (95% CI, 1.2–1.9) higher risk of PCSM and risk increased with the number of at-risk genotypes carried (Ptrend = 0.001), adjusting for clinicopathologic factors known to influence prognosis. Conclusion: Five genetic markers were validated to be associated with lethal prostate cancer. Impact: This is the first population-based study to show that germline genetic variants provide prognostic information for prostate cancer-specific survival. The clinical utility of this five-SNP panel to stratify patients at higher risk for adverse outcomes should be evaluated. Cancer Epidemiol Biomarkers Prev; 20(9); 1928–36. ©2011 AACR.Keywords
All Related Versions
This publication has 74 references indexed in Scilit:
- Vitamin D pathway gene variants and prostate cancer prognosisThe Prostate, 2010
- Genetic variation in RNASEL associated with prostate cancer risk and progressionCarcinogenesis, 2010
- CYP17 polymorphisms and prostate cancer outcomesThe Prostate, 2010
- Inherited genetic variant predisposes to aggressive but not indolent prostate cancerProceedings of the National Academy of Sciences, 2010
- Clinical utility of five genetic variants for predicting prostate cancer risk and mortalityThe Prostate, 2008
- Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2008
- Association of Megalin Genetic Polymorphisms with Prostate Cancer Risk and PrognosisClinical Cancer Research, 2008
- Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic StudyAmerican Journal of Epidemiology, 2008
- Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical ProstatectomyJNCI: Journal of the National Cancer Institute, 2006
- Coordination of circadian timing in mammalsNature, 2002